FY2025 · ended Dec 31, 2025 · Revenue $1.17B, -2.7% YoY · Filed Feb 26, 2026
Ingevity Corporation (NGVT) files with the SEC under industry code 2800, Chemicals & Allied Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 billion and a net loss of $167.1 million. Free cash flow was $273.5 million. As of Jun 30, 2026 it held $97.4 million in cash and investments and $180.1 million in total debt.
Revenue (TTM)
$1.16B
+10.6% vs year-ago TTM
Net income (TTM)
$54.00M
+124.9% vs year-ago TTM
Operating cash flow (TTM)
$211.00M
-2.0% vs year-ago TTM
Free cash flow (TTM)
$154.90M
+3.1% vs year-ago TTM
EPS (TTM)
$1.51
+125.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
35.29M
-2.9% vs prior year
Net cash
$-82.70M
as of Jun 30, 2026
Operating margin
35.9%
FY 2025
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- NGVT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- North Charleston, SC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1653477
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Innospec Inc. IOSP
- Chemours Co CC
- OLIN Corp OLN
- Huntsman CORP HUN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.7B | $1.4B |
| Operating income | $418.7M | $425.9M | $423.2M | $452.6M | $422.2M |
| Net income | -$167.1M | -$430.3M | -$5.4M | $211.6M | $118.1M |
| Diluted EPS | -$4.61 | -$11.85 | -$0.15 | $5.50 | $2.95 |
| Operating cash flow | $331.2M | $128.6M | $205.1M | $313.4M | $293.3M |
| Free cash flow | $273.5M | $51.0M | $95.3M | $170.9M | $189.5M |
| Total assets | $1.7B | $2.0B | $2.6B | $2.7B | $2.5B |
| Total liabilities | $1.6B | $1.8B | $2.0B | $2.0B | $1.8B |
| Stockholders' equity | $29.7M | $195.2M | $631.4M | — | — |
| Cash and investments | $78.1M | $68.0M | $95.9M | $76.7M | $310.7M |
| Total debt | $180.1M | $215.0M | $252.8M | $160.1M | $175.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 24, 2026 | Jun 22, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 4, 2026 | Apr 29, 2026 |
All 658 Ingevity Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.